D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 56 Citations 11,962 117 World Ranking 2109 National Ranking 32

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Immune system
  • Pathology

Philippe Gevaert spends much of his time researching Immunology, Nasal polyps, Immunoglobulin E, Sinusitis and Asthma. His Immunology research includes themes of Airway, Disease and Microbiology. His Nasal polyps study is related to the wider topic of Internal medicine.

His Immunoglobulin E study combines topics in areas such as Superantigen, Granulocyte and Atopy. His Sinusitis research is multidisciplinary, relying on both Evidence-based practice, Position paper and Intensive care medicine. His Asthma research integrates issues from Nasal spray and Allergy.

His most cited work include:

  • European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (1843 citations)
  • EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists (1518 citations)
  • Differentiation of chronic sinus diseases by measurement of inflammatory mediators. (555 citations)

What are the main themes of his work throughout his whole career to date?

Philippe Gevaert mainly investigates Immunology, Nasal polyps, Immunoglobulin E, Internal medicine and Asthma. His Immunology research is multidisciplinary, incorporating elements of Disease and Pathology. His research in Nasal polyps intersects with topics in Chronic rhinosinusitis, Surgery, Sinusitis, Dupilumab and Omalizumab.

His Immunoglobulin E research focuses on Interleukin 5 and how it relates to Eosinophil. His research investigates the link between Internal medicine and topics such as Placebo that cross with problems in Nasal congestion. He studied Asthma and Intensive care medicine that intersect with Position paper.

He most often published in these fields:

  • Immunology (47.77%)
  • Nasal polyps (36.16%)
  • Immunoglobulin E (25.00%)

What were the highlights of his more recent work (between 2018-2021)?

  • Nasal polyps (36.16%)
  • Chronic rhinosinusitis (15.18%)
  • Internal medicine (19.64%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Nasal polyps, Chronic rhinosinusitis, Internal medicine, Asthma and Omalizumab. His study in Nasal polyps is interdisciplinary in nature, drawing from both Mepolizumab, Surgery, Sinusitis, Adverse effect and Dupilumab. He interconnects Dermatology, Sinus and Otorhinolaryngology in the investigation of issues within Chronic rhinosinusitis.

His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Placebo. His work deals with themes such as Pharmacy, Chronic inflammatory disease, Allergy and Intensive care medicine, which intersect with Asthma. His Allergy study is focused on Immunology in general.

Between 2018 and 2021, his most popular works were:

  • European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (1843 citations)
  • Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. (50 citations)
  • The role of mobile health technologies in allergy care: An EAACI position paper (35 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Immune system
  • Pathology

Nasal polyps, Intensive care medicine, Asthma, Allergy and Omalizumab are his primary areas of study. His work carried out in the field of Nasal polyps brings together such families of science as Paranasal sinuses, Chronic rhinosinusitis, Surgery, Sinusitis and Dupilumab. His Intensive care medicine research includes elements of Disease susceptibility, Position paper, Evidence-based medicine and Asthma therapy.

The concepts of his Asthma study are interwoven with issues in Allergen immunotherapy, Quality of life, Airborne allergen and Reimbursement. Philippe Gevaert has researched Allergy in several fields, including Adverse effect and Disease. The various areas that Philippe Gevaert examines in his Omalizumab study include Quality of life, Placebo, Double blind, Medical physics and Internal medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

Wytske J. Fokkens;Valerie J. Lund;Joachim Mullol;Claus Bachert.
Rhinology (2012)

5065 Citations

European Position Paper on Rhinosinusitis and Nasal Polyps 2020

Wytske J. Fokkens;Valerie J. Lund;Joachim Mullol;Claus Bachert.
Rhinology (2020)

1843 Citations

Total and specific IgE in nasal polyps is related to local eosinophilic inflammation.

Claus Bachert;Philippe Gevaert;Gabriele Holtappels;S.G.O. Johansson.
The Journal of Allergy and Clinical Immunology (2001)

777 Citations

Differentiation of chronic sinus diseases by measurement of inflammatory mediators.

T. Van Zele;S. Claeys;P. Gevaert;G. Van Maele.
Allergy (2006)

772 Citations

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

Philippe Gevaert;Lien Calus;Thibaut Van Zele;Katrien Blomme.
The Journal of Allergy and Clinical Immunology (2012)

575 Citations

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.

Philippe Gevaert;Nicholas Van Bruaene;Tom Cattaert;Kristel Van Steen.
The Journal of Allergy and Clinical Immunology (2011)

570 Citations

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

Claus Bachert;Claus Bachert;Leda Mannent;Robert M Naclerio;Joaquim Mullol.
JAMA (2016)

534 Citations

Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis.

Thibaut Van Zele;Philippe Gevaert;Jean-Baptiste Watelet;Geert Claeys.
The Journal of Allergy and Clinical Immunology (2004)

463 Citations

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.

Philippe Gevaert;Doris Lang-Loidolt;Andreas Lackner;Heinz Stammberger.
The Journal of Allergy and Clinical Immunology (2006)

445 Citations

T-cell regulation in chronic paranasal sinus disease

Nicholas Van Bruaene;Claudina Angela Pérez-Novo;Tomasz M. Basinski;Thibaut Van Zele.
The Journal of Allergy and Clinical Immunology (2008)

398 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Philippe Gevaert

Claus Bachert

Claus Bachert

Ghent University

Publications: 323

Peter Hellings

Peter Hellings

KU Leuven

Publications: 138

Robert C. Kern

Robert C. Kern

Northwestern University

Publications: 107

Jean Bousquet

Jean Bousquet

Inserm : Institut national de la santé et de la recherche médicale

Publications: 106

Robert P. Schleimer

Robert P. Schleimer

Northwestern University

Publications: 95

Nikolaos G. Papadopoulos

Nikolaos G. Papadopoulos

University of Manchester

Publications: 87

Cezmi A. Akdis

Cezmi A. Akdis

University of Zurich

Publications: 73

Pascal Demoly

Pascal Demoly

University of Montpellier

Publications: 66

Noam A. Cohen

Noam A. Cohen

University of Pennsylvania

Publications: 63

Rudolf Valenta

Rudolf Valenta

Medical University of Vienna

Publications: 61

Leslie C. Grammer

Leslie C. Grammer

Northwestern University

Publications: 59

Graham Roberts

Graham Roberts

University of Southampton

Publications: 58

Gabriele Holtappels

Gabriele Holtappels

Ghent University

Publications: 57

Ioana Agache

Ioana Agache

Transylvania University of Brașov

Publications: 57

Ludger Klimek

Ludger Klimek

Ghent University

Publications: 56

Giorgio Walter Canonica

Giorgio Walter Canonica

Humanitas University

Publications: 53

Something went wrong. Please try again later.